Get the Stockscreener App
198.38
0.35%
0.70
Pre-market:
198.98
0.60
+0.30%
Natera Inc stock is traded at $198.38, with a volume of 1.14M.
It is up +0.35% in the last 24 hours and down -6.09% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$197.68
Open:
$199.53
24h Volume:
1.14M
Relative Volume:
0.98
Market Cap:
$28.12B
Revenue:
$2.31B
Net Income/Loss:
$-208.16M
P/E Ratio:
-129.10
EPS:
-1.5366
Net Cash Flow:
$76.11M
1W Performance:
-0.29%
1M Performance:
-6.09%
6M Performance:
+13.08%
1Y Performance:
+32.92%
1-Day Range:
$197.75
$203.29
1-Week Range:
$186.07
$203.29
52-Week Range:
$125.38
$256.36
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
198.38 | 28.02B | 2.31B | -208.16M | 76.11M | -1.5366 |
|
TMO
Thermo Fisher Scientific Inc
|
472.71 | 174.60B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
195.21 | 135.34B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
586.98 | 46.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
112.75 | 31.60B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
296.99 | 28.45B | 3.17B | 642.63M | 516.49M | 10.77 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Insider Selling: Natera (NASDAQ:NTRA) Director Sells 122 Shares of Stock - MarketBeat
Natera director Chapman sells $23348 in shares By Investing.com - Investing.com India
Natera Looks Compelling As Oncology Testing Momentum Keeps Building (NASDAQ:NTRA) - Seeking Alpha
Natera named Healthcare Technology Company of the Year - The Healthcare Technology Report.
Assessing Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch - simplywall.st
Holocene Advisors LP Decreases Stock Holdings in Natera, Inc. $NTRA - MarketBeat
Boothbay Fund Management LLC Increases Position in Natera, Inc. $NTRA - MarketBeat
Natera executive chairman sells $38.3 million in NTRA stock - Investing.com
NeoGenomics, Natera, and Amphastar Pharmaceuticals Stocks Soar—Key Information You Should Be Aware Of - Bitget
NeoGenomics, Natera, and Amphastar Pharmaceuticals shares skyrocket, what you need to know - MSN
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - TradingView
Why Natera Stock Is Surging On Fresh Optimism - TipRanks
NTRA Debuts Zenith Genomics Next-Gen Sequencing Test for Rare Diseases - Yahoo Finance
Natera (NTRA) Highlights Promising Results for Signatera in Canc - GuruFocus
Natera ctDNA test shows promise in anal, rectal cancer studies - Investing.com
Natera ctDNA test shows promise in anal, rectal cancer studies By Investing.com - Investing.com India
Fred Alger Management LLC Buys 41,303 Shares of Natera, Inc. $NTRA - MarketBeat
Farallon Capital Management LLC Sells 568,357 Shares of Natera, Inc. $NTRA - MarketBeat
Cancer DNA test ties anal and rectal tumors to relapse odds - Stock Titan
Natera launches whole genome sequencing test for rare diseases - Investing.com Nigeria
Coatue Management LLC Takes Position in Natera, Inc. $NTRA - MarketBeat
Capital Impact Advisors LLC Boosts Stock Position in Natera, Inc. $NTRA - MarketBeat
Aquatic Capital Management LLC Increases Position in Natera, Inc. $NTRA - MarketBeat
Pinnbrook Capital Management LP Makes New $5.78 Million Investment in Natera, Inc. $NTRA - MarketBeat
Guidance Update: Can Natera Inc keep up with sector leadersPortfolio Gains Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Natera Launches Zenith Genomics To Expand Rare Disease Testing Story - simplywall.st
Zenith Genomics Launch Could Be A Game Changer For Natera’s (NTRA) Rare Disease Strategy - Yahoo Finance
Meridiem Capital Partners LP Invests $11.90 Million in Natera, Inc. $NTRA - MarketBeat
Quantitative Investment Management LLC Acquires 6,152 Shares of Natera, Inc. $NTRA - MarketBeat
16,650 Shares in Natera, Inc. $NTRA Purchased by Magnetar Financial LLC - MarketBeat
Korea Investment CORP Cuts Position in Natera, Inc. $NTRA - MarketBeat
MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 - Sahm
MyOme Debuts Zenithtm Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 - lelezard.com
[144] Natera, Inc. SEC Filing - Stock Titan
GeneDx stock falls as Natera launches competing rare disease test - Investing.com UK
GeneDx stock falls as Natera launches competing rare disease test By Investing.com - Investing.com Australia
Natera announces commercial launch of Zenith genomics - TipRanks
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis - BioSpace
Natera, Inc. $NTRA Shares Sold by Swiss National Bank - MarketBeat
Natera, Inc. $NTRA Shares Bought by Franklin Resources Inc. - MarketBeat
Capital Fund Management S.A. Buys 41,307 Shares of Natera, Inc. $NTRA - MarketBeat
Natera director Sheena Jonathan sells $25924 in stock - Investing.com Australia
Natera president Fesko sells $144k in shares By Investing.com - Investing.com Canada
Natera president Fesko sells $144k in shares - Investing.com
Natera director Sheena Jonathan sells $25924 in stock By Investing.com - Investing.com India
Natera: Daniel Rabinowitz sells $356k in shares By Investing.com - Investing.com India
Natera: Daniel Rabinowitz sells $356k in shares - Investing.com UK
Insider Selling: Natera (NASDAQ:NTRA) CEO Sells 5,623 Shares of Stock - MarketBeat
Natera (NASDAQ:NTRA) Insider John Fesko Sells 707 Shares of Stock - MarketBeat
Michael Burkes Brophy Sells 785 Shares of Natera (NASDAQ:NTRA) Stock - MarketBeat
Natera CEO Steven Chapman sells $1.15 million in shares - Investing.com Nigeria
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):